Background: The accuracy and convenience of pen devices for insulin injection have improved quality of life for patients with insulin-treated diabetes mellitus (DM). Prefilled, disposable pens have the advantage of simplicity, with minimal training and attention required and these offer improvements in compliance, freedom and flexibility. Objective: The survey assessed doctor preference in prescribing insulin in a FlexPen™ in diabetes patients in the Philippines under normal clinical practice conditions. The data was based from obser vations on the use of NovoMix® 30 FlexPen™ (Biphasic Insulin Aspart 30). Data was collected from 256 doctors who were specialised in treating patients with diabetes and had their clinics in the Philippines. A Doctor Preference Q u e s t i o n n a i r e w a s d e v e l o p e d t o a s s e s s d o c t o r preference in specific terms of ease of learning and teaching use of FlexPen™, time spent for patient training in use of FlexPen™, ease of setting up the required dose of FlexPen™, DoctorÊs satisfaction of shifting from any other device to FlexPen™, confidence that the correct amount of insulin will be injected, feedback about the NovoFine® 30G needles, overall experience with FlexPen™. Results: In total, 256 doctors participated and completed the doctor satisfaction questionnaires. Majority of doctors 62.1% felt learning/ teaching the use of FlexPen™ to the patients was "very easy‰; and 66.8% healthcare professionals (doctor or their staff) spent less than 10 minutes to train the patients on how to use FlexPen™. About 96% doctors responded that it is very easy or easy to set up the required dose and dose correction using FlexPen™. About (98.8%) doctors were confident or very confident that their patients will inject the correct dosage of insulin using FlexPen™. Almost all doctors (98.4%) satisfied or very satisfied about the patient shifting from other insulin devices to FlexPen™; 39.5% doctors rated the design of FlexPen™ as excellent; 55.5% rated it as good; while 74.6% doctors rated the overall experience of FlexPen™ as excellent. Conclusion: The par ticipating doctors showed high degree of acceptance of Flexpen™. The overall experience of Flexpen™ was excellent. K e y w o r d s : D i a b e t e s , p r e-f i l l e d i n s u l i n p e n , Flexpen™.
Objective. To present the results from the Philippine cohort of the A1chieve study receiving insulin detemir (IDet) ± oral antidiabetic drugs.Methodology. A1chieve is a multinational, 6-month, observational study of 66,726 people with type 2 diabetes mellitus (T2DM), both insulin users and non-insulin users, started on IDet, insulin aspart or biphasic insulin aspart in 28 countries across four continents. This subgroup analysis evaluates the safety and effectiveness of IDet in 988 subjects from the Philippines.Results. At baseline the mean age, duration of diabetes and mean BMI were found to be 57±11.9 yrs, 6.9±5.3 yrs and 26±4.8 kg/m 2 respectively. Majority of subjects were insulin-naive (84.3%) and glycemic control was poor in all the groups at baseline. At the end of 24 weeks, there were significant improvements following IDet initiation with a 2.1% reduction in mean HbA1c. The HbA1c target of <7% was achieved by 46.8% subjects at the study end. Although not statistically significant, there was a modest decrease in body weight in all the groups. There was no increase in the incidence of hypoglycemia among baseline insulin-naive subjects, while a significant reduction in hypoglycemia was seen among prior insulin users.Conclusions. IDet appears to be an effective and safe option for individuals with T2DM in the Philippines. HbA1C was lowered to target, and there was no increase in incidence of hypoglycemia and body weight with IDet.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.